Scientific publications 

Post-transplant lymphoproliferative disease after liver transplantation

Herrero JI (1), Panizo C (2).

(1) Medicina Interna, Clínica Universidad de Navarra, España.
(2) Instituto de Investigación Sanitaria de Navarra (IdiSNA). Pamplona.

Magazine: Revista Española de Enfermedades Digestivas

Date: Jan 12, 2018

Hematología y Hemoterapia [SP] Hepatology


We have read the article "Post-transplant lymphoproliferative disease in liver transplant recipients" with great interest.

This article reports a series of liver transplant recipients with post-transplant lymphoproliferative disease (PTLD). The effect on patient survival and the potential benefit of rituximab-based therapy are highlighted. Rituximab is a chimeric antibody against the CD20 surface marker.

This marker is found in most PTLD of a B cell origin. A recent study from our center also highlighted the role of rituximab in PTLD therapy (3). The overall response rate of patients treated with rituximab was 66% in both series.

In our series, this included heart, kidney and liver transplant recipients. Rituximab-based therapy was also associated with an increased overall survival. Rituximab should be considered as part of the first-line therapy in patients with PTLD when CD20 expression is present.

CITATION  Rev Esp Enferm Dig. 2018 Jan 9;110. doi: 10.17235/reed.2017.5387/2017

you maybe interested


The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra


The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra


Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra